Search results
Showing 31 to 45 of 101 results for kidney cancer
Biographies and registered interests for members of the Technology Appraisal Committee A
Trabectedin for the treatment of advanced soft tissue sarcoma (TA185)
Evidence-based recommendations on trabectedin (Yondelis) for treating advanced soft tissue sarcoma in adults.
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treating and preventing deep vein thrombosis and pulmonary embolism in adults.
Irreversible electroporation for treating liver metastases (IPG445)
Evidence-based recommendations on irreversible electroporation for the treatment of liver metastases. This involves using very short electrical field pulses delivered over several minutes to destroy the tumour and a small surrounding tissue margin.
View recommendations for IPG445Show all sections
Sections for IPG445
Evidence-based recommendations on Ixazomib (Ninlaro) with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663)
Evidence-based recommendations on venetoclax (Venclyxto) with obinutuzumab for untreated chronic lymphocytic leukaemia in adults.
This guideline covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It includes advice on diagnosis, education and support, blood glucose management, cardiovascular risk, and identifying and managing long-term complications.
The NGAL Test for early diagnosis of acute kidney injury (MIB3)
NICE has developed a medtech innovation briefing (MIB) on the NGAL Test for early diagnosis of acute kidney injury .
Irreversible electroporation for treating primary lung cancer and metastases in the lung (IPG441)
Evidence-based recommendations on irreversible electroporation for treating primary lung cancer and metastases in the lung. This involves using electrical pulses to kill cancer cells.
View recommendations for IPG441Show all sections
Sections for IPG441
Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (DG11)
Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative
Urinary tract infection (recurrent): antimicrobial prescribing (NG112)
This guideline sets out an antimicrobial prescribing strategy for preventing recurrent urinary tract infections in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.
Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.
Minimally invasive video‑assisted parathyroidectomy (IPG501)
Evidence-based recommendations on minimally invasive video-assisted parathyroidectomy. This involves inserting surgical instruments through a small cut (keyhole surgery) to find and remove any abnormal glands.
Suspected sepsis: recognition, diagnosis and early management (NG51)
This guideline covers the recognition, diagnosis and early management of suspected sepsis. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.
Show all sections
Sections for NG51
- Overview
- Could this be sepsis?
- Face to face assessment
- Under 16s: evaluating risk and managing suspected sepsis
- Pregnant or recently pregnant people: evaluating risk and managing suspected sepsis
- Over 16s (not pregnant or recently pregnant): evaluating risk and managing suspected sepsis
- Antibiotic therapy, intravenous fluid and oxygen
- Finding and controlling the source of infection
Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)
Summary of the evidence on oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia to inform local NHS planning and decision-making